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Opportunities and challenges in
incorporating ancillary studies into a cancer
prevention randomized clinical trial
Phyllis J. Goodman1*, Catherine M. Tangen1, Amy K. Darke1, Kathryn B. Arnold1, JoAnn Hartline2, Monica Yee2,
Karen Anderson2, Allison Caban-Holt3, William G. Christen4, Patricia A. Cassano5, Peter Lance6, Eric A. Klein7,
John J. Crowley2, Lori M. Minasian8 and Frank L. Meyskens9
Abstract
Background: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a randomized, double-blind,
placebo-controlled, prostate cancer prevention study funded by the National Cancer Institute and conducted
by SWOG (Southwest Oncology Group). A total of 35,533 men were assigned randomly to one of four treatment
groups (vitamin E + placebo, selenium + placebo, vitamin E + selenium, placebo + placebo). At the time of the trial’s
development, NIH had invested substantial resources in evaluating the potential benefits of these antioxidants.
To capitalize on the knowledge gained from following a large cohort of healthy, aging males on the effects of
selenium and/or vitamin E, ancillary studies with other disease endpoints were solicited.
Methods: Four ancillary studies were added. Each drew from the same population but had independent objectives
and an endpoint other than prostate cancer. These studies fell into two categories: those prospectively enrolling and
following participants (studies of Alzheimer’s disease and respiratory function) and those requiring a retrospective
medical record review after a reported event (cataracts/age-related macular degeneration and colorectal screening).
An examination of the challenges and opportunities of adding ancillary studies is provided. The impact of the ancillary
studies on adherence to SELECT was evaluated using a Cox proportional hazards model.
Results: While the addition of ancillary studies appears to have improved participant adherence to the primary trial, this
did not come without added complexity. Activation of the ancillary studies happened after the SELECT randomizations
had begun resulting in accrual problems to some of the studies. Study site participation in the ancillary trials varied
greatly and depended on the interest of the study site principal investigator. Procedures for each were integrated into
the primary trial and all monitoring was done by the SELECT Data and Safety Monitoring Committee. The impact of the
early closure of the primary trial was different for each of the ancillary trials.
Conclusions: The ancillary studies allowed study sites to broaden the research opportunities for their participants. Their
implementation was efficient because of the established infrastructure of the primary trial. Implementation of these
ancillary trials took substantial planning and coordination but enriched the overall primary trial.
Trial registration: NCT00006392-S0000: Selenium and Vitamin E in Preventing Prostate Cancer (SELECT) (4 October 2000).
NCT00780689-S0000A: Prevention of Alzheimer’s Disease by Vitamin E and Selenium (PREADVISE) (25 June 2002).
NCT00784225-S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men
on SELECT SWOG-S0000 (SEE) (31 October 2008).
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NCT00706121-S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-
S0000 (ACP) (26 June 2008).
NCT00063453-S0000C: Vitamin E and/or Selenium in Preventing Loss of Lung Function in Older Men Enrolled on SELECT
Clinical Trial SWOG-S0000 (26 June 2003).
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Background
The Selenium and Vitamin E Cancer Prevention Trial
(SELECT) was a randomized, double-blind, placebo-
controlled, prostate cancer prevention study funded by
the National Cancer Institute (NCI) and the National
Center for Complementary and Alternative Medicine
(NCCAM) and conducted by SWOG (formerly known
as the Southwest Oncology Group) [1]. Between August
2001 and June 2004, 35,533 men were assigned ran-
domly to one of four groups: vitamin E + placebo, selen-
ium + placebo, vitamin E + selenium, placebo + placebo.
Accrual to the trial came from more than 400 study sites
in the US, Puerto Rico, and Canada. On 15 September
2008, the independent Data and Safety Monitoring
Committee (DSMC) recommended discontinuation of
study supplements because of lack of efficacy for risk
reduction, and because futility analyses demonstrated no
possibility of benefit from the supplements to the antici-
pated degree, i.e., 25 % reduction in prostate cancer inci-
dence, with continued supplementation and additional
follow-up [2]. A CONSORT diagram for the primary ana-
lysis is presented in Additional file 1. An updated analysis
[3] in October 2011 revealed that the men who had been
taking vitamin E and the selenium placebo had a 17 %
increased risk of prostate cancer compared to the men
who took two placebos (p = .008). The study sites ended
their participation, and 17,781 participants agreed to con-
tinue providing regular health updates to the Statistical
Center in the Centralized Follow-up (CFU) [4] phase.
At the time of the development of SELECT, the Na-
tional Institutes of Health (NIH) had invested substantial
resources in evaluating the use of nutritional supple-
ments. In particular, there was scientific interest in the
potential benefits of antioxidants, including funding for
large trials such as the Heart Outcomes Prevention
Evaluation (HOPE), which examined the effects of vita-
min E on cardiovascular risk in a high-risk population,
and the Age-Related Eye Disease Study (AREDS), which
examined the effects of vitamin C, vitamin E, beta-
carotene, and zinc on the progression of age-related
macular degeneration. Given the size of SELECT, there
was a desire to capitalize on the knowledge gained from
following a large cohort of healthy, aging males on the
effect of selenium and/or vitamin E on other disease
endpoints within the trial.
From the perspective of the funding agencies, ancillary
studies are a cost-effective mechanism to answer import-
ant questions in the same population as the randomized
trial, using pre-existing clinical study sites with reduced
recruitment efforts and use of existing study data. The
purpose of this paper is to describe both the opportun-
ities and challenges of incorporating ancillary studies
into an active clinical trial.
Methods
SELECT was coordinated by SWOG, a national consor-
tium of institutions and investigators that conducts multi-
disciplinary clinical trials to improve the practice of
medicine in preventing, detecting, and treating cancer,
and to enhance the quality of life for cancer survivors. Pri-
mary support for SWOG comes from the National Cancer
Institute (NCI). Institutions across the US that enroll
patients into SWOG group studies include those affiliated
with major academic medical centers and their associated
affiliate institutions, and Community Clinical Oncology
Program (CCOP) sites, which are community hospitals or
consortia with a mandate for both clinical research and
cancer control, including prevention research.
Recruitment to SELECT was from SWOG, other co-
operative oncology groups, the Department of Veterans
Affairs (VA), study sites that had successfully partici-
pated in other large prevention trials, as well as 13
Canadian institutions. Within the cooperative groups,
CCOPs provided 30 % of the total accrual.
Researchers with an interest in launching an ancillary
study were asked to submit a proposal to the SELECT
Executive Committee, comprising SWOG, SELECT, and
NCI leadership, for review. Proposals were reviewed for
scientific merit and feasibility, and were assessed in
terms of required sample size, participant characteristics
of the target population, data collection methodology
and potential impact on the primary trial. Funding was
required to cover costs of the study sites to do the work
required of the ancillary study, as well as the costs of the
SELECT Statistical Center to implement the required
changes to the existing study and general study support.
Four ancillary trials were activated within SELECT: (1)
Prevention of Alzheimer’s Disease with Vitamin E and
Selenium (PREADVISE), (2) the SELECT Eye Endpoint
(SEE) study, (3) the Respiratory Ancillary Study (RAS),
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and (4) the Adenomatous Colorectal Polyps (ACP)
study. Common characteristics of these studies included
study objectives independent of prostate cancer preven-
tion with hypotheses that involved either selenium,
vitamin E, or the combination of the two. Each ancillary
study had a project team that was independent from SE-
LECT and was responsible for protocol development
and a chapter for the SELECT Study Manual. They used
the SELECT participant data, specimens and data man-
agement, and were comanaged by SELECT and the inde-
pendent ancillary study teams. Each ancillary study
required Institutional Review Board (IRB) approval by
participating study sites and written informed consent
from participants. The SELECT Statistical Center
worked with the ancillary study teams on issues related
to data transfers and reports to facilitate study and par-
ticipant management.
Potential opportunities that could result from the
addition of the ancillary studies included (1) increased
research options for participants, (2) enhanced accrual
to the primary trial, and (3) improved adherence to the
primary trial. In order to evaluate the impact of adher-
ence to SELECT we implemented a Cox proportional
hazards model, where time until the participant went off
treatment was the dependent variable and participation
in an ancillary study was a time-dependent covariate be-
cause enrollment could have been post randomization to
SELECT. This analysis was limited to the two ancillary
studies that required active follow-up (PREADVISE and
RAS). Participants who went off treatment for reasons
other than the development of prostate cancer or death
and prior to the release of study results and suspension
of study supplements (23 October 2008) were consid-
ered an event; participants who went off treatment due
to either development of prostate cancer, death or the
study termination were censored at the time of their
competing event. Covariates included in the model were
age (50–64 years versus 65–74 years versus 75 years and
older), African American race (yes/no), Hispanic ethni-
city (yes/no), whether the participant was enrolled at a
site that participated in either PREADVISE or RAS (yes/
no), smoking status (current versus never/former), edu-
cation (college or greater versus other), marital status
(married versus other), and BMI (<25 versus 25–29.9
versus ≥30). Interaction terms for ancillary study partici-
pation, race, ethnicity, and age were also included.
All men randomized on SELECT who provided informed
consent were included in the analysis excluding men who
(1) had a pre-randomization diagnosis of prostate cancer or
(2) were from sites in Puerto Rico. Puerto Rican sites were
excluded due to the small sample size. Analysis was done
in SAS version 9.2 using PROC PHREG.
In addition to the opportunities, there was also the
anticipation of individual study challenges as well as
some that would bridge all of the trials. These included
(1) initial activation of the trial, (2) buy-in from the
study sites, (3) integration of study procedures, (4) com-
munication, and (5) study monitoring. The early closure
of SELECT was another unanticipated challenge.
Results
The four ancillary studies implemented within SELECT
fell into one of two categories: (1) a study requiring ac-
tive interaction with the participant with prospective
data collection or (2) a study requiring a retrospective
medical record review based on a reported non-prostate
cancer event (Table 1).
Studies requiring active participation
PREADVISE
The first ancillary study activated was the Prevention of
Alzheimer’s Disease by Vitamin E and Selenium (PREAD-
VISE), funded by the National Institute on Aging [5–7].
The objective of this study was to evaluate the effect of
Table 1 SELECT and the approved ancillary studies
Primary
endpoint
Activation
date
Last registration date # men # sites Study site recruitment base Follow-up procedure
SELECT Prostate
cancer
July 2001 June 2004 35,533 427 Cooperative Group; Veterans
Admin Cooperative Studies program;
sites involved in other large prevention
trials (WHI, HOPE); Canadian urologic sites
Active follow-up every
6 months
PREADVISE Alzheimer’s
disease
May 2002 Sept 2009 7553 128 All invited Active follow-up/memory
screens
RAS COPD June 2004 April 2007 2921 18 20 sites with high proportion
of smokers
Active follow-up/pulmon-
ary function tests
SEE Cataracts
and AMD
July 2004 Dec 2009 2436 105 All invited Medical record review
ACP Colorectal
adenomas
June 2008 May 2013 8089 76 100 sites with large number
of men; men on Centralized
Follow-up
Medical record review
ACP Adenomatous Colorectal Polyps study, AMD age-related macular degeneration, COPD chronic obstructive pulmonary disease, PREADVISE Prevention of Alzhei-
mer’s Disease with Vitamin E and Selenium, RAS Respiratory Ancillary Study, SEE SELECT Eye Endpoint study
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selenium and vitamin E in combination and alone on the
reduction of the clinical incidence of Alzheimer’s disease
(AD). Registered participants were screened annually for
memory issues with the Memory Impairment Screen
(MIS) [8]. For those men who failed the MIS screen, a
second stage of screening consisting of an expanded men-
tal status examination using a subset of the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD)
battery of mental status tests [9] was administered by
study site staff and results were sent to the PREAD-
VISE Coordinating Center. Failure on both the brief
and expanded screenings suggests problems with cog-
nition and memory. These participants were asked to
sign a second consent form to obtain a medical work-
up for treatable causes of memory loss. The age eligi-
bility criteria for PREADVISE was older than that for
SELECT (62 versus 55 years) which was later lowered
to 60 years or above for African Americans. The ac-
crual goal was 10,400 participants from all SELECT
study sites.
RAS
The Respiratory Ancillary Study (RAS) was funded by the
National Heart, Lung and Blood Institute and also required
active participation [10, 11]. The objective of this study was
to understand whether vitamin E and/or selenium can slow
the loss of lung function that occurs naturally with aging.
The accrual goal was 3000 participants, with as many
current smokers as possible. Participants were followed
with regular pulmonary function tests (PFT).
Studies requiring medical record review
SEE
The SELECT Eye Endpoints (SEE) study was funded by
the National Eye Institute [12]. The accrual goal was
for 700 men who had age-related macular degener-
ation (AMD) events and 2240 men with cataract
events. Men at participating study sites who reported
the development of a cataract post randomization, or
a diagnosis of AMD by responding positively to
vision-related questions, were approached to partici-
pate in this study. Consenting participants provided a
Medical Release Form, and the SEE Statistical Center
gathered the records for review.
ACP
The Adenomatous Colorectal Polyps (ACP) study was
funded by the NCI [13]. Men who reported a colorectal
endoscopic screening procedure (colonoscopy or sig-
moidoscopy) were asked to participate. The primary aim
was to determine whether the study interventions re-
duced colorectal adenoma occurrence. Adenoma recur-
rence was determined by review of endoscopy records
followed by confirmation from histology reports of the
presence of one or more adenomas. The study site pro-
cedures were similar to those for SEE, with the addition
of a required tissue sample. The goal was to capture
8000 procedures.
Opportunities
Increased study options for participants
The ability of participants to register to the ancillary
studies depended on the interest of their local study site.
The level of study site participation in the ancillary stud-
ies varied greatly and is discussed in detail later. For two
of the studies, RAS and ACP, the sites with the largest
accrual to SELECT were specifically recruited to partici-
pate as they provided the biggest potential return for the
time and money invested in starting up a new study.
The smaller sites had the opportunity to participate in
two studies (PREADVISE and SEE) but as can be seen in
Table 2 only 22 % of the smallest sites (1–25 partici-
pants) chose to participate. For medium size sites (26–
100 participants), 51 % of the sites participated in at
least one ancillary study.
Registrations to the ancillary studies took place
throughout the course of SELECT (Table 3). Ultimately
14,923 men, 42 % of the SELECT population, partici-
pated in at least one of the ancillary studies; 597 men
participated in all four. The overlap of the participation
in the studies can be seen in Fig. 1. For ease of presenta-
tion, the two studies only requiring medical record re-
view are grouped together.
Improved adherence to primary trial
Participant characteristics for all of SELECT and for the
two ancillary studies requiring active participation are pre-
sented in Table 4. The biggest differences are in the age
distribution, race, and smoking status due to differing
Table 2 Number of ancillary studies in which study sites participated by size of study site
Number of ancillary studies
Number of participants on SELECT N sites of this size None n (%) One n (%) Two n (%) Three n (%) Four n (%)
≤25 participants 167 130 (78 %) 23 (14 %) 6 (4 %) 8 (5 %) 0 (0 %)
26–100 participants 172 84 (49 %) 48 (28 %) 30 (17 %) 10 (6 %) 0 (0 %)
101–500 participants 74 20 (27 %) 22 (30 %) 18 (24 %) 13 (18 %) 1 (1 %)
>500 participants 12 2 (17 %) 2 (17 %) 3 (25 %) 2 (17 %) 3 (25 %)
Total 425 236 95 57 33 4
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registration requirements. After accounting for the covari-
ates, participation in an ancillary study improved adher-
ence to the primary trial, as defined by time until the
participant went off both study supplements. The hazard
ratio for time until off for those participating at a site
which participated in either PREADVISE or RAS was 0.80
(95 % confidence interval 0.75–0.86, p < .0001), meaning
that the rate of going off study supplements was 20 % less
for participants whose site was involved in ancillary stud-
ies than for those that were not at such sites.
Challenges
Study activation
Accrual to SELECT took two fewer years than origin-
ally planned. Because of the start-up and planning
time needed for the ancillary studies, the rapid accrual
to SELECT meant that activation of the ancillary trials
happened after SELECT randomizations began. This
was particularly difficult for the trials that actively
followed participants and their need for baseline, pre-
randomization data.
The first registration to PREADVISE was 10 months
after SELECT began randomizing participants. An extra
2 years of accrual would have given the staff at the study
sites additional time to learn and incorporate study pro-
cedures that were different than those for an oncology
trial. As it became apparent that the SELECT accrual
period would be shorter than planned, it became clear
that the accrual goal for PREADVISE would not be
reached. At the time SELECT closed accrual, 3858 men
had been registered to PREADVISE. Changes were made
to the PREADVISE eligibility requirements that allowed
registration to PREADVISE after the participant was
randomized to SELECT. The sample size was also modi-
fied downwards to 6500.
RAS was activated the month that SELECT accrual
ended. Because the participants were to be accrued after
randomization to SELECT, and no baseline measures
would be available, the RAS incorporated objectives that
were assessed in both longitudinal and cross-sectional
analyses while taking advantage of the randomization.
Participants were followed annually for 3 years; these
visits coincided with the SELECT annual visits.
For the two studies that involved submission of source
documentation after a reported event during SELECT
follow-up, the rapid accrual was not an issue.
Buy-in from study sites and participant accrual
As the first activated ancillary study, PREADVISE was
the first to experience the reluctance of some of the
study sites to participate. Sites were surveyed as to their
interest in participating and to identify barriers to par-
ticipation. The primary barriers were lack of staff time,
perceived complexity of baseline and follow-up require-
ments, burden on SELECT study site staff, lack of famil-
iarity with memory impairment screening and cognitive
endpoints, lack of interest by the site principal investiga-
tor (PI), and inadequate compensation. Regulatory and
IRB issues were related to absence of language regarding
the potential risks, consent for the use of SELECT speci-
mens for the genetic screening of ApoE alleles, and the
re-consent process for participants who met the criteria
for cognitive impairment. Efforts to make PREADVISE
appeal to more study sites included reducing data require-
ments, in-person training opportunities, the addition of
receptions at the SELECT semiannual training workshops
Table 3 Timing of registration to ancillary study and randomization to SELECT
Years between randomization and registration to ancillary study (number of men)a
0b 1 2 3 4 5 6 7 Post SELECT unblinding
PREADVISE 2095 2216 952 185 428 815 416 110 267
SEE 0 68 182 355 535 424 290 67 510
RAS 141 489 1125 1157 7 1 0 0 0
ACP 0 0 0 0 15 75 100 96 7642
aPrior to study unblinding and cessation of supplementation
bWithin 45 days of randomization
ACP Adenomatous Colorectal Polyps study, PREADVISE Prevention of Alzheimer’s Disease with Vitamin E and Selenium, RAS Respiratory Ancillary Study, SEE SELECT
Eye Endpoint study
PREADVISE RAS
SEE or ACP
N=597
N=482N=3908
N=2504 N=690
N=1151
N=5528
N=35,533
SELECT
20,610
No ancillary study
Fig. 1 Overlap of participation in the ancillary studies
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for participating clinical research associates (CRAs), the
addition of tools to assist with the registration and follow-
up processes and increased site payments which included
both a per capita reimbursement as well as funds to
support the process of getting the protocol passed by local
IRBs. Ultimately, 152 sites said they would participate in
PREADVISE but only 128 of 427 (30 %) of sites registered
participants. The final accrual was 7553.
All sites were encouraged to participate in SEE and it
was expected that most sites would participate due to
the limited additional work to register participants.
However, the anticipated time and effort needed to ac-
complish additional tasks, such as obtaining local IRB
approval, explaining the study to potential participants,
administering a new informed consent and assisting the
participant in completing the Medical Release Form, was
considered by many sites to be insufficiently covered by
the reimbursement. Sites were surveyed as to whether or
not a modest increase in the amount of support would
change their ability to participate. However, survey re-
sults indicated that the proposed payment increase
would not have a substantial impact on study site par-
ticipation. The large majority of sites that participated in
SEE felt that the methodology was simple and easy to
implement and did not place an excessive burden on
staff. Ultimately, 148 study sites obtained IRB approval
with 105 of these study sites registering 2436 men to the
study. Among the registered men, there were enough
Table 4 Participant characteristics
SELECT PREADVISE RAS
Age (years)
Median (IQ range) 62 (58,67) 65 (61,69) 61 (57,66)
50–54 1480 4.2 % 38 0.5 % 207 7.1 %
55–64 20,347 58.3 % 3567 47.7 % 1784 68.2 %
65–74 10,808 31.0 % 3260 43.6 % 795 27.2 %
75+ 2252 6.5 % 619 8.3 % 134 4.6 %
Race/ethnicity
White 27,571 79.0 % 6121 81.8 % 2006 68.7 %
African American 4286 12.3 % 660 8.8 % 694 23.8 %
Hispanic (non-African American) 1196 3.4 % 198 2.7 % 73 2.5 %
Hispanic (AA) 356 1.0 % 31 0.4 % 19 0.7 %
Other 1478 4.2 % 474 6.3 % 128 4.4 %
Education
≤ High school graduate 7682 22.0 % 1560 20.8 % 674 23.1 %
Some college/vocational school 9355 26.8 % 1960 26.2 % 850 29.1 %
≥ College graduate 17,515 50.2 % 3931 52.5 % 1371 47.0 %
Unknown 335 1.0 % 33 0.4 % 25 0.9 %
Marital status
Currently married 28,430 81.5 % 6365 85.1 % 2189 75.0 %
Not married 6272 18.0 % 1097 14.7 % 711 24.4 %
Unknown 185 0.5 % 22 0.3 % 20 0.7 %
Smoking status
Current 2682 7.7 % 398 5.3 % 470 16.1 %
Former 17,156 49.2 % 3831 51.2 % 1393 47.7 %
Never 14,882 42.7 % 3244 43.4 % 1041 35.7 %
Unknown 167 0.5 % 11 0.2 % 16 0.6 %
BMI
< 25 6967 20.0 % 1504 20.1 % 598 20.5 %
25–30 16,751 48.0 % 3662 48.9 % 1357 46.5 %
≥ 30 10,970 31.4 % 2292 30.6 % 957 32.8 %
Unknown 199 0.6 % 26 0.4 % 8 0.3 %
BMI body mass index, IQ interquartile
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cataract endpoints but the goal for the AMD endpoint
was not reached.
The requirements to be a RAS site were identified
prior to trial activation. The smaller sample size, the
need for smokers and the need for training on adminis-
tering the pulmonary function tests (PFT) resulted in a
limited number of study sites that were invited to join
RAS. Site selection was upfront and based on the num-
ber of registered participants on SELECT, the number of
smokers, and the interest of the study site PI. A total of
18 sites participated, registering 2920 men with 16.1 %
being current smokers compared to 7.5 % on SELECT.
ACP learned from SEE that it would be more efficient
to focus recruitment efforts on a smaller number of
sites. The top accruing sites to SELECT were invited to
participate, resulting in IRB approval of 90 study sites
covering 16,899 participants. By the time the SELECT
study sites had closed, 4794 men had been registered,
short of the accrual goal of 8000.
Integration of study procedures and training
A key component to ensuring successful implementation
of the ancillary studies was their full integration into SE-
LECT procedures. This included using the SWOG for-
mat for the protocol and Informed Consent Form as
well as using the central participant registration program
and study forms that complied with SELECT guidelines.
Each ancillary study team was responsible for a chapter
in the SELECT Study Manual outlining study proce-
dures at the study sites, including participant recruit-
ment and follow-up, data management, endpoint
reporting, and any additional biologic specimen needs.
In order to integrate the ancillary studies as seamlessly
as possible, all forms were developed using the same
software, and were maintained along with the ancillary
Study Manual on the SELECT website.
For PREADVISE and RAS, another integration issue
was how and when to present the ancillary study to
potential participants without overburdening the par-
ticipant with too much information. A participant was
introduced to PREADVISE at the discretion of the
CRA at his study site either at the participant’s SE-
LECT randomization visit or at any subsequent visit.
This flexibility also allowed time for younger partici-
pants to become age-eligible for PREADVISE. Because
of study activation issues, RAS was also introduced to
participants at a post-baseline visit which also reduced
the amount of information presented to the partici-
pants at any one time.
Training opportunities provided by the ancillary stud-
ies included those directed at study site staff and others
aimed directly at the participants. In addition to their
sections in the SELECT Study Manual which contained
training materials, each ancillary study had sessions at
the SELECT semi-annual training workshop which in-
cluded large didactic presentations, smaller break-out
sessions, open forums, poster sessions, and informal
gatherings where the CRAs had a chance to interact
with ancillary study staff. Other training tools were by
the ancillary study staff and were dependent on available
funding and staff time for development (Table 5).
Coordinating this effort across the primary trial and the
four ancillary trials was challenging but resulted in dy-
namic training workshops.
Communication
As with any large collaborative effort, communication
between all interested parties is paramount to success
but can be difficult to achieve. A variety of tools were in
place to facilitate communication with the study sites
and between the SELECT team and the ancillary study
teams. The SELECT Workbench, the on-line collection
of protocols, manual, documents, and procedures used
for all aspects of the management of SELECT, was main-
tained by the SELECT Statistical Center and was the
portal for participant registrations and data submission
for the ancillary studies. As a result, there was a need for
constant communication between the ancillary study
teams and the SELECT Statistical Center concerning
ancillary study data collection, materials provided on the
website, and study status. Additionally, various reports
were developed and produced routinely for the coordin-
ating centers of the ancillary studies including (1) study
site IRB approval status, (2) lists of potentially eligible
and registered participants, (3) monthly accrual and
basic demographics, and (4) data needed for evaluation
of the study. These reports were generally run in batch
and placed on secure File Transfer Protocol (FTP) sites.
Evaluated endpoint data collected from the external an-
cillary study teams were put on the secure FTP sites,
uploaded to the secure SWOG database, and were used
Table 5 Training, adherence, and retention tools and their use
by each ancillary study
PREADVISE RAS SEE ACP
Study Manual X X X X
Workshop X X X X
In-person study site training X
Study website for participants X
Participant newsletter X
Staff newsletter/tip sheets/updates X X
Participant incentive items X X
Staff incentive items X X
Conference calls with study sites X X
ACP Adenomatous Colorectal Polyps study, PREADVISE Prevention of Alzheimer’s
Disease with Vitamin E and Selenium, RAS Respiratory Ancillary Study, SEE SELECT
Eye Endpoint study
Goodman et al. Trials  (2016) 17:400 Page 7 of 10
by the SELECT statistical staff to prepare the annual
DSMC reports.
Conference calls with the SELECT study team and the
ancillary study teams were held on a regular basis (PRE-
ADVISE and ACP) as well as on an as-needed basis
(SEE and ACP). The calls were an opportunity to ad-
dress implementation issues and other time-sensitive
concerns. They also more generally served the purpose
of providing an avenue for open conversation between
the groups.
Ancillary study PIs were incorporated into the study
leadership by serving as members of the SELECT Steer-
ing Committee and joining the Executive Committee
monthly calls as needed. They also had periodic meet-
ings with NCI leadership to speak about unique study is-
sues without the immediate SELECT leadership present.
Communication with the study site staff regarding
data collection on the ancillary studies was done through
the SELECT Statistical Center, as it housed the data; for
other procedural issues and ancillary-specific training is-
sues the study site staff were directed to the ancillary
study team.
Monitoring
Members with expertise in the disease area of the ancil-
lary studies were added to the SELECT DSMC so that it
could function as the DSMC for the ancillary studies.
Data from the ancillaries and SELECT were monitored
at their annual meeting. There were no explicit predeter-
mined guidelines regarding what would happen to the
ancillary studies in case of early closure of SELECT. The
ancillary study PIs were concerned that endpoints for
their studies might not be completed and the invest-
ments in their studies would not be fulfilled should the
primary trial end with extreme positive or negative
results. Ultimately, the trial intervention ended early,
and the decision to continue participant follow-up via
the CFU was made in part to allow time for the ancillary
studies to gather as much additional data as possible to
answer their study questions.
Impact of early closure of SELECT and transition to Centralized
Follow-up
After the early release of study results, SELECT study
sites continued to follow their participants with in-
person visits. Follow-up transitioned to a CFU model
[4] and 17,607 men agreed to be followed annually.
Due to the status of each of the ancillary studies, the
shift in how participants were followed impacted each
differently.
PREADVISE had not finished collecting their primary
study data and needed continued follow-up. Procedures
were modified so that staff at their Coordinating Center
could collect follow-up by telephone using the Telephone
Interview for Cognitive Status-Modified (TICS-M) [14] to
replace the MIS and a Long Memory and Thinking Screen
(LMTS). This entailed a major protocol amendment with
a new Informed Consent Form and the subsequent secure
transfer of personal identifiers (including name, telephone
number) from the SELECT Statistical Center to enable
them to contact participants directly. Of the 6957 PRE-
ADVISE men who were alive and willing to be followed
by their study site, 62 % agreed to be contacted by staff at
the PREADVISE Coordinating Center.
The transition to CFU created some opportunities
for PREADVISE. The ability to communicate directly
with the participants allowed PREADVISE to establish
its own identity with the men. Updates to participant
survival status from these contacts were transmitted
back to the SELECT Statistical Center. The transition
also afforded PREADVISE the ability to have more
control of the study procedures including the ability
to utilize trained examiners for administration of the
MIS and follow-up procedures for the participants be-
ing followed [15, 16].
For RAS, when study supplementation stopped, the
PFT endpoint was available for only 57 % of their partic-
ipants, resulting in the loss of power for the primary
analysis of lung function decline over 3 years. The final
PFTs were done while the participants were off supple-
ments and still being followed by the study sites.
At the time of the transition to CFU, ACP had accrued
about half of its goal. Men who were registered to the
SELECT CFU but had been at sites not participating in
ACP were now able to register. A letter of invitation,
Medical Release and Informed Consent Forms were sent
to men who had reported a colorectal screening proced-
ure. This approach yielded an additional 3303 partici-
pants for a total of 8097 participants, enabling the trial
to meet its accrual goal.
SEE had accrued enough men to answer its cataract
objective but did not have enough AMD endpoints. The
CFU provided the ability to identify additional incident
AMD cases from men not at SEE sites.
Discussion
The incorporation of ancillary studies into a large on-
going randomized trial presents both opportunities and
challenges. The concentration of research resources
including the identification of study sites, recruitment
plans, training venues, data and study management pro-
cedures, and overall administrative and statistical sup-
port makes for an efficient study model. These studies
also enhance collaboration between researchers inter-
ested in similar agents across a variety of disease areas.
For the ancillary studies, the advantages to joining
forces with an existing trial were clear. Advantages to
the primary trial were also evident, specifically, increased
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recruitment potential, improved adherence, and the abil-
ity of study sites to broaden research opportunities for
their participants. SELECT recruited its 35,533 men
2 years ahead of schedule and prior to the full imple-
mentation of some of the ancillary studies, such that the
impact of ancillary studies on accrual to the main trial
was minimal. The impact on adherence to the primary trial
was substantial; men who were at sites that participated in
an ancillary study were 20 % less likely to stop study supple-
ments. However, this analysis was limited because we may
not have adequately captured participant factors that could
have influenced registration to the ancillary studies or study
site factors that may also have been important.
There were challenges in these collaborations. SELECT
was ultimately a prostate cancer prevention trial and study
implementation procedures were driven by this endpoint.
As a result, for the ancillary studies, there was a loss of
control of study and participant management, as it was
necessary that their procedures fit within the primary trial.
For some ancillaries this entailed an increase in the com-
plexity of procedures that were otherwise simple and
straightforward to implement. There were also issues of
integrating a non-cancer study into an oncology setting
(e.g., reluctance of CRAs to collect different types of data)
and the need to conform to NCI and SWOG require-
ments. Changes in study site leadership also proved chal-
lenging when a new study site PI was not interested in or
committed to the ancillary study and did not provide
adequate support to implement the study.
For the SELECT Statistical Center, the ancillary studies
provided additional funding to cover tasks necessary for
their successful integration into SELECT. However, the
additional tasks to implement and coordinate the studies
were greater than had been expected and funding did
not fully cover the increased workload.
The early closure of SELECT directly impacted the an-
cillary studies. In addition, had there been either an
extreme positive or negative result of one of the ancillary
studies prior to the closure of SELECT, the DSMC would
have had to decide what to do with the primary trial.
While there were no guidelines for this situation, the
DSMC had been monitoring outcome data from the
primary trial and the ancillary studies since their incep-
tion, and thus had the global picture of all of the trials and
would have been in a good position to make this decision.
The continued responsibility to publish the trial results
and for ongoing data analyses of both the primary trial
and the ancillary studies requires persistence by the
remaining staff to ensure that the investment of this large
collaboration yields as much science as possible.
Conclusion
As a general population study, SELECT presented op-
portunities to look at other health areas. These ancillary
study endpoints were not secondary outcomes of the
primary trial but rather were independent primary ana-
lyses in imbedded trials. Ancillary studies as add-ons to
clinical trials provide the opportunity to conduct re-
search using an existing infrastructure. Such studies are
encouraged by the NIH and at any given time there is a
multitude of funding opportunities for such studies
through the individual institutes. The benefits to the
parent trial can be tangible in terms of recruitment and
adherence but also extend beyond the time of the active
intervention and follow-up. The benefits and potential
drawbacks to the ancillary studies should be weighed
and discussed with the primary statistical center prior to
joining the main study, for the benefit of all researchers
and participants.
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